Page 7 - Evolve Biosystems News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article DAVIS, Calif., March 11, 2021 /PRNewswire/ -- Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children.  The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries. The Leona M. and Harry B. Helmsley Charitable Trust is funding the study and the continuation of the established newborn screening with more than $30 million. ...

Day One highlights Microbiome through life: Exploring new science and commercial strategies from the first 1,000 days to healthy aging. The day features Francesco Asnicar, University of Trento; John Deaton, Deerland Probiotics & Enzymes; Jennifer Gu, AIDP, Inc; Lindsay Hall, Quadram Institute and the Technical University of Munich; David Kyle, Evolve BioSystems, Inc.; Stephen Lindemann, Purdue University and Nathan Price, Institute for Systems Biology and Onegevity Health. Day Two will look at New opportunities and developing ideas in the science and business of the microbiome and will fea...

Investing in the Future of Food: Manna Tree investors seek emerging brands focused on human health As the ongoing pandemic accelerates consumer interest in the role of nutrition in wellness and underscores the supply chain’s fragility, the investors at Manna Tree Partners are looking for at least three growth stage companies that are revolutionizing the production, delivery and consumption of food to support human health. With $235 million in assets under its management as of last month and six investments already in its portfolio to date, Manna Tree’s managin...

Pre-term infants fed with B. Infantis experienced lower level of intestinal inflammation Researchers publishing in the peer-review journal Frontiers in Pediatrics report that pre-term infants fed Bifidobacterium longum subsp. infantis (activated B. infantis EVC001) experienced significantly lower level of intestinal inflammation, 62% less diaper rash, and required 62% fewer antibiotics- all of which are critical health indicators in neonatal care. The study, Impact of probiotic B. infantis EVC001 feeding in premature infants on the gut microbiome, nosocomially acquired antibiotic resistanc...

Dairy Dialog podcast 121: Tate & Lyle, Evolve Biosystems, Bridge Cheese Dairy Dialog podcast 121: Tate & Lyle, Evolve Biosystems, Bridge Cheese This week we feature three interviews, with five guests. We have conversations with Timothy Brown, CEO of Evolve BioSystems and Pam Shepherd, managing director of Manna Tree; Jim Carr, PhD, director, sweeteners global ingredient technology and Abigail Storms, vice president of sweetener innovation at Tate & Lyle; and Michael Harte, managing director of Bridge Cheese. We also have our weekly look at the global dairy markets ...